BIG PHARMA EARNINGS WATCH: ASTRAZENECA AND NOVARTIS
May 1, 2025
Big Pharma Giants Report Strong Earnings Beating Analysts’ Expectations… Read More
© 2026 CSRXP- All Rights Reserved
Updates
BIG PHARMA EARNINGS WATCH: ABBVIE, ROCHE, GILEAD, MERCK AND BRISTOL MYERS SQUIBB
May 1, 2025
Merck CEO Acknowledges Americans Paying Highest Drug Prices in the World as… Read More
CSRxP LAUNCHES SIX-FIGURE ADVERTISING CAMPAIGN TO HOLD BIG PHARMA ACCOUNTABLE FOR ANTICOMPETITIVE PRACTICES AND EGREGIOUS DRUG PRICING
Apr 28, 2025
Campaign Spoofs Big Pharma’s Direct-to-Consumer (DTC) Ads While Highlighting… Read More
DOSE OF REALITY: BIG PHARMA’S PATENT ABUSE EXTENDING MONOPOLIES, KEEPING PRICES HIGH ON GLP-1S
Apr 22, 2025
Novo Nordisk Alone Has Filed 320 Patents on Single Active Ingredient Behind… Read More
BIG PHARMA EARNINGS WATCH: JOHNSON & JOHNSON
Apr 16, 2025
Big Pharma Giant Johnson & Johnson Reports Earnings That Beating Wall… Read More
CSRxP STATEMENT ON U.S. SENATE AND U.S. HOUSE REINTRODUCTION OF Q1/Q2 REFORMS TO FOSTER GREATER COMPETITION, LOWER DRUG PRICES
Apr 15, 2025
Lawmakers Should Advance Bipartisan Solution to Crack Down on Anti-Competitive… Read More
THEY SAID IT! SENATE JUDICIARY CALLS OUT BIG PHARMA’S ANTI-COMPETITIVE PRACTICES THAT KEEP PRESCRIPTION DRUG PRICES HIGH
Apr 7, 2025
Senators on Both Sides of the Aisle Highlight Concerns with Big Pharma’s… Read More
CSRxP STATEMENT ON SENATE JUDICIARY PASSAGE OF BIPARTISAN, MARKET-BASED SOLUTIONS TO HOLD BIG PHARMA ACCOUNTABLE, LOWER DRUG PRICES
Apr 3, 2025
Committee Markup Advances Legislation to Crack Down on Big Pharma’s… Read More
BIG PHARMA WATCH: PFIZER AVOIDED PAYING BILLIONS IN U.S. TAXES THROUGH “EGREGIOUS TAX GIMMICK”
Apr 2, 2025
Big Pharma Giant Used “Round-Tripping” Tax Avoidance Scheme to Attribute… Read More
FACT SHEET: BIG PHARMA’S PATENT ABUSE COSTS AMERICAN PATIENTS, TAXPAYERS AND THE U.S. HEALTH CARE SYSTEM BILLIONS OF DOLLARS
Apr 2, 2025
BIG PHARMA’S PATENT ABUSE IS THE ROOT CAUSE OF OUT-OF-CONTROL PRESCRIPTION… Read More
CSRxP ANALYSIS FINDS BIG PHARMA’S DIRECT-TO-CONSUMER (DTC) ADVERTISING COSTS U.S. TAXPAYERS BILLIONS OF DOLLARS
Mar 18, 2025
Study Finds Reducing or Taxing Brand Name Drug Companies’ Nearly $14 Billion… Read More
CSRxP APPLAUDS U.S. SENATE REINTRODUCTION OF BIPARTISAN, MARKET-BASED SOLUTIONS TO LOWER DRUG PRICES BY ADDRESSING BIG PHARMA’S PATENT ABUSE
Mar 14, 2025
Cracking Down on Anti-Competitive Tactics Like Patent-Thicketing and… Read More